PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Ustekinumab - Inflammatory bowel disease

PAD Profile : Ustekinumab - Inflammatory bowel disease Important

Keywords :
IBD, biologics, biosimilars, Sequential use of biologic medicines, Interleukin, IL 12/23 , Cytokine modulator, Crohn's disease, Ulcerative Colitis, UC
Brand Names Include :
Stelara
Important Information :
Adults only.

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Intravenous infusion
  • Subcutaneous injection (sc)
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD1
ICB
BlueTeq
NICE
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date
Guidelines (Local)
IBD - High Cost Immunomodulator Pathway April 2024.pdf
NICE Technology Appraisal
NICE TA456 -Ustekinumab for moderately to severely active Crohn’s disease after previous treatment - July 2017
NICE Technology Appraisal
NICE TA633- Ustekinumab for treating moderately to severely active ulcerative colitis - June 2020
Evidence Review
Ustekinumab 8 weekly dose escalation evidence paper April 2019.pdf
01 April 2022
Evidence Review
Ustekinumab in Ulcerative Colitis - NICE TA633 briefing paper - August 2020.pdf

Committee Recommendations

Date
Committee Name
Narrative
04 October 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated IBD immunomodulator pathway.

05 August 2020
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

ULCERATIVE COLITIS

The Surrey & North West Sussex Area Prescribing Committee recommends ustekinumab for treating moderately to severely active ulcerative colitis in line with NICE TA633. 

The Area Prescribing Committee also agreed an update of treatment pathway 4 (high cost immunomodulator) for use in Inflammatory Bowel Disease. The Crohn's Disease Pathway and the Ulcerative Colitis Pathway are now incorporated into one document 

03 April 2019
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

CROHN'S DISEASE

The Surrey and North West Sussex Area Prescribing Committee recommends that ustekinumab in patients with moderately to severely active Crohn’s Disease, may be dose optimised to 8 weekly when a patient starts to lose response to standard (12 weekly) dosing.  Dose optimisation will be for a 16 week treatment course to recapture response.

Patients must return to standard dosing (ustekinumab 12 weekly) after the 16 week course has been completed. 

If the patient loses response to the standard dosing within a short time period (12 weeks) then the provider can apply for maintenance funding to return to the escalated dose (8 weekly).

Gastroenterologists can repeat the 16 week course if the patient starts to lose response after returning to 12 weeks of standard dosing.

Ustekinumab is a payment by results excluded drug and will be considered RED on the traffic light system.

Gastroenterology specialists will be required to complete blueteq initiation and continuation forms for the commissioners.

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication

02 August 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

CROHN'S DISEASE

The PCN recommends Ustekinumab as a treatment option for treating moderately to severely active Crohn’s Disease in line with NICE and the associated treatment pathway. Prescribing will be by hospital specialists only, in line with NICE TA456 using Blueteq initiation and continuation forms. Ustekinumab will be considered RED on the traffic light system

Associated BNF Codes

01. Gastro-Intestinal System
01.05.03. Drugs affecting immune response
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More